Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 13/20 | 0.42 |
| ▸ | HTR2C | P28335 | 13/20 | 0.42 |
| ▸ | HTR1A | P08908 | 3/20 | 0.40 |
| ▸ | HTR7 | P34969 | 3/20 | 0.40 |
| ▸ | CSF1R | P07333 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2201116 | 0.88 | MEN1 (0.41) | HTR2AHTR2CHTR1AHTR7CSF1R | |
| SCHEMBL2198513 | 0.87 | HTR2A (0.49) | HTR2AHTR2CCSF1R | |
| SCHEMBL2200461 | 0.86 | HTR2C (0.48) | HTR2AHTR2CCSF1R | |
| SCHEMBL2200789 | 0.81 | MAPT (0.50) | HTR2C | |
| SCHEMBL2201731 | 0.80 | JAK2 (0.40) | — | |
| SCHEMBL2195866 | 0.80 | ALDH1A1 (0.47) | HTR2AHTR2CHTR1AHTR7CYP1A2 | |
| SCHEMBL2198505 | 0.79 | TP53 (0.40) | — | |
| SCHEMBL2202819 | 0.79 | MEN1 (0.46) | CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL2200821 | 0.79 | CSF1R (0.41) | CSF1R | |
| SCHEMBL4351675 | 0.79 | CSF1R (0.43) | HTR2AHTR2CHTR1AHTR7CSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2116530-B1 | NOVEL PYRROLE DERIVATIVE HAVING UREIDE GROUP AND AMINOCARBONYL GROUP AS SUBSTITUENTS | SANTEN PHARMACEUTICAL CO LTD (JP) | 2012-11-14 | — | — | EP | claimed |
| US-7977371-B2 | Pyrrole derivative having ureido group and aminocarbonyl group as substituents | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-07-12 | — | — | US | claimed |
| US-20100099675-A1 | NOVEL PYRROLE DERIVATIVE HAVING UREIDO GROUP AND AMINOCARBONYL GROUP AS SUBSTITUENTS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-04-22 | — | — | US | claimed |
| EP-2116530-A1 | NOVEL PYRROLE DERIVATIVE HAVING UREIDE GROUP AND AMINOCARBONYL GROUP AS SUBSTITUENTS | Santen Pharmaceutical Co., Ltd (JP) | 2009-11-11 | — | — | EP | claimed |
| US-7977371-B2 | Pyrrole derivative having ureido group and aminocarbonyl group as substituents | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-07-12 | — | — | US | disclosed |
| US-20100099675-A1 | NOVEL PYRROLE DERIVATIVE HAVING UREIDO GROUP AND AMINOCARBONYL GROUP AS SUBSTITUENTS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099675-A1 | NOVEL PYRROLE DERIVATIVE HAVING UREIDO GROUP AND AMINOCARBONYL GROUP AS SUBSTITUENTS | UACA, IL6, IL6ST | HTR2A 2928/4885HTR2C 2790/4885HTR1A 3369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.